Expression of a bovine vesicular monoamine transporter in COS cells  by Gasnier, Bruno et al.
FEBS Letters 342 (1994) 225-229 
LETTERS 
FEBS 13855 
Expression of a bovine vesicular monoamine transporter in COS cells 
Bruno Gasniera, Eric Krejcib, Damien Bottona, Jean MassouliCb, Jean-Pierre HenryaT* 
“Service de Neurobiologie Physico-Chimique, CNRS Unit& AssociPe 1112, Institut de Biologie Physico-Chimique, 13 rue Pierre et Marie Curie, 
7500s Paris, France 
bLaboratoire de Neurobiologie, CNRS Unit& Associke 295, Ecole Normale Supckieure, 46 rue d’Ulm, 75005 Paris, France 
Received 31 January 1994; revised version received 21 February 1994 
Abstract 
Catecholamines are accumulated in vesicles by a proton gradient-dependent transport, which has mostly been studied in bovine chromaffin 
granules. The full sequence of a cDNA encoding a vesicular transporter from bovine chromaffi cells, bVMAT*, was recently reported. We now 
present an analysis of bVMAT,, expressed in transfected COS cells. Comparing the binding of a labelled ligand, [‘HITBZOH, and the rate of uptake, 
we find a much lower molecular turnover number than in chromaffin granules, probably indicating that a majority of expressed transporters are 
correctly folded and possess the ligand binding site but cannot actively transport monoamines because they are located in compartments which do 
not possess a proton gradient. The substrate specificity of uptake and its pharmacological sensitivity to various inhibitors closely resemble those 
previously observed in chromaffin granules. These results suggest that VMAT, is the major transporter in bovine adrenal glands, and raise the question 
of the significance of the second related transporter, VMAT,, which is also expressed in this tissue. 
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1. Introduction 
In endocrine or neuronal monoaminergic cells, the 
monoamines (or their precursors) are transported and 
stored in vesicles prior to their release. The transport is 
catalyzed by a specific protein, the vesicular monoamine 
transporter, which utilizes the energy of the H’ electro- 
chemical gradient generated by an ATP-dependent H’ 
pump of the V type [l-3]. The transporter has a low 
substrate specificity since it transports all monoamines 
as well as other non-physiological compounds, such 
as MIBG (meta-iodobenzylguanidine) [4] or MPP’ 
(1 -methyl-4-phenylpyridinium) [5]. 
The molecular properties of the vesicular monoamine 
transporter have been investigated by biochemical and 
pharmacological approaches. For the latter approach, 
several igands were developed which bind specifically to 
the vesicular monoamine transporter [6]. Dihydrotetra- 
benazine (TBZOH) and ketanserin bind to the same site 
with dissociation constants in the nanomolar concentra- 
tion range, and binding is unaffected by the H’ electro- 
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Abbreviations: bVMAT, bovine vesicular monoamine transporter; 
TBZ, tetrabenazine; TBZOH, 2-hydroxy-3-isobutyl-9,10-dimethoxy- 
1,2,3,4,6,7-hexahydro-1 lb (H)benzo[l]quinolizine; [3H]TBZOH, [2- 
‘Hldihydrotetrabenazine; RES, reserpine; MPP’, I-methyld-phenyl- 
pyridinium; MIBG, meta-iodobenzylguanidine; CCCP, carbanylcya- 
nide m-chlorophenylhydrazone. 
chemical gradient. On the other hand, reserpine binding 
(Ko 30 PM) is dependent upon the proton gradient since 
it is strongly accelerated when the H’ pump is activated, 
thus suggesting the existence of a different binding site. 
These studies, which were performed mostly on the 
chromaffin granules of bovine adrenal medulla but also 
on various rodent tissues [7,8], did not suggest any hetero- 
geneity of the vesicular monoamine transporter, for in- 
stance between neuronal and endocrine tissues. The ve- 
sicular monoamine transporter has recently been cloned 
in rat [9, lo], bovine [ 11,121 and human [ 131. Surprizingly, 
in rat two cDNA clones were described [9] which encode 
two related proteins. These proteins have the same gen- 
eral organization with 12 putative transmembrane do- 
mains, and a large intravesicular loop located between 
transmembrane segments 1 and 2. The first gene, 
VMAT, (formerly named CGAT) was reported to be 
expressed in adrenal medulla but not in brain, whereas 
the converse is true for the second one, VMAT* (for- 
merly named SVAT). In transfected CHO cells, VMAT, 
induced an efficient transport activity. However, this 
transport was sensitive to TBZ only in the micromolar 
concentration range. Erickson et al. [lo] independently 
obtained a clone identical to VMAT2 and reported that 
the encoded transporter was more sensitive to TBZ. 
The interpretation of the existence of two genes encod- 
ing VMAT has been complicated by the recent finding 
[l 1,121 that in bovine adrenal medulla a gene highly 
related to VMAT, was expressed at a high level. This 
gene, bVMAT,, was assumed to encode the vesicular 
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monoamine transporter since the protein sequence de- 
rived from bVMAT, contained peptides determined by 
sequencing the bovine protein. 
In the present communication, we describe the expres- 
sion of bovine VMAT2 in COS cells and we characterize 
the corresponding activity by assaying ATP-dependent 
[3H]noradrenaline uptake and [3H]TBZOH binding. 
2. Materials and methods 
2.1. Transfections 
The complete bVMAT, clone [1 1] was subcloned into the pCDM8 
expression vector. The corresponding nucleotide data sequence was 
registered in the EMBL, Genbank and DDBJ Nucleotide sequence 
Databases under accession number X76380. Transfections in COS-7 
cells were performed as described [14]. 
2.2. [‘HlNoradrenaline uptake and [-‘H]TBZOH binding 
Three days after transfection, cells were scraped into ice-cold 0.3 M 
sucrose/IO mM HEPES (Na+) buffer, pH 7.6, containing 1 mM EGTA, 
5 @g/ml aprotinin and 6 &ml leupeptin. The suspension was homoge- 
nized with a glass-Teflon homogenizer and centrifuged for 5 min at 
1,500 x g to remove cell debris. Homogenates were used within 24 h of 
their preparation. Noradrenaline uptake was measured as described 
previously [I 51, using undiluted [3H]noradrenaline (16 Wmmol) from 
Amersham and HAWP filters (Millipore). For competition experi- 
ments, different procedures were followed for substrates (catecholam- 
ines, serotonin, MPP’ and MIBG) and for inhibitors (RES, TBZ and 
ketanserin), in order to reach steady-state conditions in all cases. For 
transport experiments, the homogenate was preincubated for 15 min in 
the presence of ATP-Mg, and the uptake was initiated by the simulta- 
neous addition of [3H]noradrenaline (0.08 flM final concentration) and 
the competitor. In the second case, the homogenate was preincubated 
for 90 min in the presence of ATP-Mg and of the inhibitor. In both 
cases, uptake was stopped by dilution with ice-cold buffer. 
TBZOH binding was measured as described [16], using [‘HITBZOH 
(11.4 Ci/mmol) from C.E.A. (Saclay, France) and HAWP filters (Mil- 
lipore). In competition experiments, homogenates were incubated for 
9 h in the presence of 4.8 nM [‘HITBZOH and various concentrations 
of competitor. 
3. Results 
COS cells were transfected with bVMAT, inserted into 
the pCDM-8 vector [17], as described previously [14]. 
After 3 days, the cells were homogenized and the homo- 
genate was incubated with [3H]noradrenaline, in the 
presence of ATP. We observed an uptake of radioactivity 
(Fig. 1A). [3H]Noradrenaline could be released by os- 
motic shock, thus indicating that it was accumulated in 
closed membrane structures. As in the case of chromaffin 
granules, this process was ATP-dependent and driven by 
an H+ electrochemical gradient, presumably generated 
by a V-type proton pump since it was inhibited by the 
H’ ionophore, CCCP (Fig. lA, inset). The uptake was 
blocked by 20 j.~uM TBZ and 2 PM RES. The TBZ- 
sensitive [3H]noradrenaline uptake was not observed in 
non-transfected COS cells, in cells treated without DNA, 
or in cells transfected with the vector alone (see 
Fig. 1B). 
In the presence of ATP, the TBZ-sensitive [3H]norad- 
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Fig. 1. [3H]Noradrenaline transport in bVMAT,-transfected COS cells. 
(A) Accumulation of noradrenaline as a function of time. The cell 
homogenate (0.5 mg of protein/ml) was preincubated for 15 min at 
28°C in 0.3 M sucrose, 2.5 mM ATP, 1.25 mM MgS04, 10 mM HEPES 
@la’) buffer pH 7.6, with (w) or without (0) 5 PM TBZ. Uptake was 
initiated by the addition of 0.1 PM [‘Hlnoradrenaline. Non-linear re- 
gression analysis of the data gave an exponential curve with tnz = 10.5 
min (r = 0.977). (Inset) The cell homogenate was preincubated in the 
presence of ATP-Mg (l&4), 20 PM TBZ (2), 2 PM RES (3) or 10 PM 
CCCP (4) and incubated for 30 min with [‘Hlnoradrenaline (l-5). In 
(5), ATP was omitted. (B) Saturation isotherm. Uptake was measured 
after a 4-min incubation at different [‘Hlnoradrenaline concentrations. 
The results are the means of three determinations. The TBZ-sensitive 
uptake (0) was obtained as the difference between transport in the 
absence (0) and in the presence (m) of TBZ. No TBZ-sensitive uptake 
could be detected in homogenates from untreated COS cells or cells 
treated in the absence of DNA, which gave results similar to those 
observed in the presence of TBZ for bVMAT,-transfected cells. (Inset) 
Lineweaver-Burke plot of the data. Linear regression indicated a V,,, 
value of 32 pmol/min/mg of protein and K, value of 1.9pM (r = 0.998). 
Similar values were obtained in an independent ransfection experi- 
ment. 
renaline uptake was linear for about 5 min (Fig. 1A). The 
transport was saturable (Fig. 1B) and linearization of the 
saturation isotherm (Fig. lB, inset) indicated a Michaelis 
constant, KM, of 1.9 PM and a maximal velocity, I’,,,,,, 
B. Gamier et al. /FEES Letters 342 (1994) 225-229 221 
z- O 







1 OS3 10-l 1 0’ 1 o3 
SUBSTRATE OR INHIBITOR (PM) 
Fig. 2. Pharmacological profiles of [‘Hlnoradrenaline uptake and 
[3H]TBZOH binding to homogenates of transfected COS cells express- 
ing bVMAT,. (A) [3H]Noradrenaline uptake. (B) [‘HITBZOH binding. 
Both activities were assayed in parallel experiments on the same homo- 
genate at 0.4 mg of protein/ml in 0.3 M sucrose, 10 mM HEPES (Na’), 
pH 7.6, containing 2.5 mM ATP, 1.3 MgSO,, and various concentra- 
tions of the competitors, at 26°C. The results are expressed as percent- 
age of the control in the absence of competitor. The following compe- 
titors were used: RES (o), TBZ (m), ketanserin (o), noradrenaline (A), 
adrenaline (0), dopamine (+), serotonin (A), MPP’ (0) and MIBG (0). 
of 32 pmol/min/mg of protein (PH 7.6,28”C). The af’fin- 
ity of the uptake system for various substrates was deter- 
mined by competition experiments (Fig. 2). ICso values 
derived from these experiments are very similar to those 
obtained previously for bovine chromaffin granules 
(Table 1). 
We also observed a saturable binding of the tritiated 
derivative TBZOH (Fig. 3A). The amount of bound li- 
gand was larger than expected from the I&,, of uptake 
(see section 4). From a Scatchard plot of a saturation 
isotherm experiment (Fig. 3B), we obtained an equilib- 
rium dissociation constant (Kn) of 6.7 nM and a number 
of binding sites (B,,,) of 4.5 pmol/mg protein (pH 7.6, 
28°C). The pharmacological profile of the TBZ binding 
sites was defined by displacement experiments (Fig. 2B). 
The corresponding I&, values (Table 1) are in reasona- 
bly good agreement with data previously reported for 
bovine chromaffin granules. 
4. Discussion 
Transfection of COS cells with bVMAT, resulted in 
the expression of an ATP-dependent noradrenaline up- 
take activity in membranes derived from the transfected 
cells. This result shows clearly that bVMAT, encodes the 
vesicular monoamine transporter. This result also shows 
that, in the non-endocrine COS cells, the vesicular 
monoamine transporter is, at least partially, addressed 
to a cellular compartment possessing an ATP-dependent 
H’ pump, since the observed [3H]noradrenaline uptake 
is ATP-dependent and is blocked by the H’ ionophore, 
CCCP. A similar conclusion has been reached for rat 
[9, lo] and human [13] vesicular transporters (rVMAT2 
and hVMAT,), which were expressed in Chinese hamster 
ovary and CV, cells, respectively. 
In the present report, however, the membranes of 
transfected cells have been tested not only for [3H]norad- 
renaline uptake, but also for [3H]TBZOH binding. 
[‘HITBZOH binding does not require an H’ electro- 
chemical gradient and it detects transporter molecules 
irrespective of their vectorial transport activity [6]. For 
instance, this ligand binds to detergent-solubilized trans- 
porter [ 181. The number of binding sites measured in 
COS cells homogenates, B,,,, was 4.5 pmol/mg of pro- 
tein, i.e. analogous to that obtained for homogenates of 
adrenal medulla or chromaffin cells, thus indicating a 
high level of expression. When ATP-dependent [3H]nor- 
adrenaline uptake was measured on the same prepara- 
tion and under the same conditions, a figure of 32 pmol/ 
min/mg of protein was derived for V,,. This figure indi- 
cates a comparatively low transport activity since the 
derived molecular turn-over number of the transfected 
transporter (V,,,IB,,, = 7 molecules/min at 25°C) is 
much lower than that obtained with intact chromalhn 
Table 1 
Pharmacological profiles of [‘Hlnoradrenaline uptake and [‘HJTBZOH 
binding in homogenates of transfected COS cells expressing bVMAT7 
Compounds ICsO GM) 
Noradrenaline uptake TBZOH binding 
bVMAT, Chromaffin bVMAT, Chromaffin 
granules granules 
RES 0.0007 0.005 
TBZ 0.027 0.012 
Ketanserin 0.170 0.07 
Serotonin 0.59 0.4 
Dopamine 1.4 
Nor- 1.7 1.4 
adrenaline 
Adrenaline 2.5 1.4 
MPP’ 9.7 1.5 










The data derived from Fig. 2 are compared to those previously obtained 
in our laboratory for bovine chromaffin granules membrane vesicles, 
according to [21] for ketanserin, [5] for MPP’ and B. Gasnier (Ph.D. 
Thesis) for the others, n.d., not determined. 
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Fig. 3. Saturation isotherm of [‘HITBZOH binding to an homogenate 
of bVMAT,-transfected COS cells. (A) The homogenate was incubated 
for 3 h at 28°C with various concentrations of [‘HITBZOH in the 
absence (D) or in the presence (m) of 5pM TBZ. These experiments were 
performed with the same homogenate as those shown in Fig. 1. (B) 
Scatchard plot of specific [‘HITBZOH binding. The results are the 
means of two determinations. A Kn value of 6.7 nM and a B,,,,, value 
of 4.5 pmol/mg of protein were derived from these data (r = 0.985). 
Similar values were obtained in an independent ransfection experi- 
ment. 
granules (140 molecules/mm) [8,19]. The low turn-over 
number in COS cells can be interpreted in several ways. 
In the first interpretation, the COS cells contain an ho- 
mogenous population of low activity transporters. Each 
individual transporter molecule expressed in COS cells 
would function at only 5% of the rate of the chromaffin 
cells transporters. This could result from an incomplete 
processing of the transporter in COS cells. On the other 
hand, if we assume that the transporter functions as a 
dimer, the high turn-over number in bovine chromaffin 
granules might reflect the activity of bVMAT,/bVMAT2 
hetero-oligomers, while bVMATz homo-oligomers 
would possess a much lower activity. 
In the second interpretation, the COS cells contain a 
majority of inactive VMAT protein and few (5%) fully 
active transporters. This second hypothesis appears 
more likely, and it would explain the apparent discrep- 
ancy between the pharmacological inhibition of binding 
and of uptake by TBZ and ketanserin (see below). The 
presence of a large pool of non-translocating transporter 
could result from incomplete processing, or from inade- 
quate subcellular localization, or both. As discussed 
above, most of the synthesized transporter molecules, 
although they could bind [3H]TBZOH, would remain 
inactive because transport activity would require post- 
translational modifications occurring in the biosynthetic 
compartments (endoplasmic reticulum, Golgi network) 
or in the acidic final compartment. It may be noted that 
the transporter is glycosylated and that it has several 
putative phosphorylation sites [ 111. We may also imagine 
that all transporters are able to transport monoamines, 
but that most of them are localized in a compartment 
which cannot generate an H’ electrochemical gradient. 
ATP-dependent noradrenaline uptake may only occur 
when the monoamine transporter is addressed to a cellu- 
lar compartment equipped with a V-type ATPase. Along 
the secretory pathway, the V-type ATPase is present in 
the trans-Golgi network and in secretory vesicles; it is 
also present along the endocytotic pathway. Accumula- 
tion of the expressed protein in the endoplasmic reticu- 
lum, possibly resulting from saturation of the secretory 
pathway because of protein over-production, might thus 
explain the low transport/binding ratio. 
In endocrine cells, the vesicular monoamine trans- 
porter might be present on Golgi-derived secretory gran- 
ules (e.g. chromaffin granules) or on synaptic-like mi- 
crovesicles which are sorted from endosomes [20]. At the 
present time, it is not known whether the two types of 
organelles utilize the same transporter or are equipped 
with two different proteins resulting from the expression 
of the two VMAT genes. The latter hypothesis would 
imply some sorting mechanism, the efficiency of which 
would depend upon the type of cell used for the transfec- 
tion. It will therefore be interesting to express bVMAT, 
in endocrine cells. 
From a practical point of view, our results show that, 
in transfected cells, transport assays are not necessarily 
more sensitive than ligand binding assays, although they 
benefit from a time-dependent amplification factor. This 
should be considered when designing strategies for ex- 
pression cloning of transport proteins. 
4.1. Pharmacological characterization of the expressed 
bVMAT, 
The pharmacological profiles of both ATP-dependent 
[3H]noradrenaline uptake and [3H]TBZOH binding have 
been analyzed (Table 1). They agree reasonably well with 
those previously reported for chromaffin granules. It 
may be noted that the afIinity for TBZ is in the nanomolar 
concentration range and that this drug blocks t3H]nor- 
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adrenaline uptake in the same range. This result differs 
from that previously reported for rVMAT,-transfected 
cells, in which the uptake was more resistant o this drug 
by several orders of magnitude [9]. The affinity for the 
substrates (5-HT > Dopamine - Noradrenaline - Adre- 
naline > MPP’), as estimated from competition experi- 
ments, can be considered to be similar to that reported 
for rat and human VMAT, in vivo [13]. It is difficult to 
appreciate whether this is significantly different from 
that reported for rVMAT, [9], for which the rank of 
order was 5-HT > Adrenaline > Dopamine > Noradre- 
naline. 
In Table 1, the comparison between the pharmacologi- 
cal data obtained for noradrenaline uptake and 
[3H]TBZOH binding deserves ome comment. It is some- 
how surprising that for the inhibitors TBZ and ket- 
anserin, which bind to the same site, larger concentra- 
tions are required to inhibit [3H]noradrenaline uptake 
than to displace bound [3H]TBZOH. The data of Fig. 2B 
show, for instance, that ketanserin at 20 nM fully occu- 
pies its site without any inhibition of ATP-dependent 
noradrenaline uptake. This is in contrast with the corre- 
lation, previously reported, between the occupancy of 
TBZ binding sites and the inhibition of monoamine up- 
take [16]. The most likely explanation is an heterogeneity 
in the transporter molecules. The active molecules, capa- 
ble of noradrenaline uptake, represent only a minor pop- 
ulation, as previously discussed. The characteristics of 
TBZ and ketanserin binding to this population would be 
different from those observed on the major population, 
because of either a different structure or a different envi- 
ronment .
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